Immunocore Holdings plc American Depositary Receipt (IMCR)
Will Kimmtrak Continue to Aid IMCR's Growth Through the Rest of 2026?
Strong demand for Kimmtrak is fueling Immunocore's growth, while potential label expansion and late-2026 data could add further upside.
IMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More Momentum
Immunocore's 3-month gain reflects Kimmtrak growth and pipeline progress, but valuation and mixed signals temper the momentum case.
Is IMCR Worth Buying as Kimmtrak Growth Meets a Premium Valuation?
Immunocore's Kimmtrak growth and late-stage catalysts strengthen its case, but a premium valuation and single-product risk raise the stakes.
IMCR Q2 Revenues Climb 18.3% as Kimmtrak Demand Helps Offset EPS Miss
Immunocore's Q2 revenue beat reflects strong Kimmtrak demand, but an EPS miss and distributor stocking headwind cloud the near-term outlook.
Immunocore's Q2 Earnings Miss Estimates, Kimmtrak Aids Y/Y Revenues
IMCR incurs wider-than-expected Q2 loss. However, revenues beat as sole drug Kimmtrak sales rise 18.3% year over year on higher U.S. and international sales.
Wall Street Analysts See a 77.91% Upside in Immunocore (IMCR): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 77.9% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Immunocore Holdings plc (IMCR) Q2 2026 Earnings Call Transcript
Immunocore Holdings plc (IMCR) Q2 2026 Earnings Call Transcript
Immunocore Q2 Earnings Call Highlights
Immunocore NASDAQ: IMCR reported continued growth for KIMMTRAK in the second quarter and first half of 2026, while advancing three late-stage melanoma trials and early-stage programs in oncology, HIV and Type 1 diabetes.
Immunocore's Kimmtrak Growth Story and Major 2026 Catalysts Ahead
IMCR's Kimmtrak sales climbed 29% in 2025 on wider adoption, with pivotal 2026 trial results set to test its next expansion opportunity.
Is Immunocore Stock Attractive After Kimmtrak's Strong Sales Growth?
Kimmtrak's sales growth supports IMCR, but premium valuation and reliance on one product keep investors focused on upcoming pipeline catalysts.
How Immunocore Is Expanding Beyond Its Rare-Cancer Drug Kimmtrak
Kimmtrak anchors IMCR today, but its broader T-cell receptor platform is targeting larger cancer, infectious disease and autoimmune markets.
Immunocore: KIMMTRAK Is Becoming A Cash Engine For A Much Larger TCR Platform
Immunocore has transitioned from a rare-disease oncology company to a self-funded platform company with a validated commercial engine. KIMMTRAK's strong global sales, five-year survival data, and operating leverage underpin IMCR's ability to fund a broad pipeline without dilutive equity. Upcoming catalysts include pivotal readouts for tebentafusp and brenetafusp in melanoma, PRAME franchise expansion, and initial data in oncology, infectious disease, and autoimmune programs.
